Yesterday, Li Xi, acting governor of Liaoning Province, visited our company's Benxi Chengda Biological Park. Ge Yu, president of Liaoning Chengda Co., Ltd., introduced the situation of Liaoning Chengda Pharmaceutical Section to the governor and his party in detail. Accompanying Governor Li Xi were Benxi City Party Secretary Li Rui and Vice Mayor Yu Hai.

Liaoning Chengda Pharmaceutical Section has two subsidiaries: one is Chengda Fangyuan Pharmaceutical Chain Investment Co., Ltd., referred to as "Chengda Fangyuan"; The second is Chengda Biology Co., Ltd., referred to as "Chengda Biology".

Chengda Fangyuan is mainly engaged in drug wholesale, chain drugstore retail and other businesses. At present, it has 6 wholly-owned or holding subsidiaries and nearly 900 retail stores, mainly covering Northeast China and opening up markets in North and East China. "Chengda Fangyuan" has won the market reputation for its honest management and enthusiastic service, and has become the "Top Ten Chain Drugstores in China" enterprise. Chengda Fangyuan is committed to becoming the most influential and respected large-scale pharmaceutical retail chain enterprise in the country.

Chengda Biology is mainly engaged in the research and development, production and sales of human vaccines. At present, the varieties on the market include "Chengda Suda" human rabies vaccine, "Chengdalibao" human Japanese encephalitis inactivated vaccine, and the upcoming human hemorrhagic fever vaccine. There are 6 varieties under research. Chengda Biology is committed to the research, production and promotion of international level and domestic leading biological products, and strives to become a respected and influential enterprise. At present, "Chengda Suda" has the first domestic market share, and is exported to more than 20 countries and regions with its own brand "SPEEDA", and its product quality has been widely praised.

Benxi Pharmaceutical Capital "Chengda Biological Park" is a biomedical industrial park built by Chengda Biology in 2009. Currently, the enterprises in the park include Liaoning Chengda Animal Pharmaceutical Co., Ltd. (Chengda Animal Pharmaceutical) and Liaoning Future Biotechnology Co., Ltd. (Future Biology). Chengda Animal Pharmaceutical is a wholly-owned subsidiary of Chengda Bio. It translates the advanced vaccine technology of the parent company and focuses on the development, production and sales of animal vaccines. The marketed "Veruicheng" veterinary rabies will definitely play an important role in the prevention and control of rabies in China.